Facebook Pixel ‘Click M' For Mental Health | BioSpectrum Asia - Business - Lees dit verhaal op Magzter.com

Poging GOUD - Vrij

‘Click M' For Mental Health

BioSpectrum Asia

|

February 2022

Mental health and wellbeing has become a major cause for concern, especially due to the pandemic-induced psychological traumas, stemming from spending long hours in the confines of one’s home, minimal to zero social interaction, inability to meet and greet friends and family, as before and financial insecurity. Little wonder that the mental health space turned out to be ‘the hot’ sector in 2021, with funding more than doubling globally, climbing from $2.3 billion to $5.5 billion. As app-based mental health solutions are becoming a rage in APAC, we take a quick look at a few promising players.

- Ayesha Siddiqui

‘Click M' For Mental Health

Mental health problems are rising worldwide and Asia Pacific is no different, with anywhere between 4 per cent and 20 per cent of the population experiencing a diagnosable mental health problem, according to a Lancet report.

Even then, mental health remained an issue largely unaddressed, almost neglected, until now. In recent times, there has been a flurry of activities and funding in the sector which aim to bridge this gap. COVID-19, focus on preventive health, limited number of psychiatrists and the narrow access to clinical treatment in the region have all fuelled the adoption of apps for such disorders.

Based on the Asia-Pacific Front Line of Healthcare Report 2019, 34 per cent of physicians believe mental health service can be delivered digitally and 20 per cent are confident it can be powered by machine learning in the next 5 years.

Market is also set to reflect that. According to a report by Market Data Forecast, the size of the mental health software market was valued at $0.31 billion in 2021 and is estimated to be growing at a CAGR of 14.86 per cent reaching $0.62 billion by 2026.

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

India–EU FTA Paves Way for Expanded Healthcare Trade

On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.

time to read

4 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

PreferCo and Glatt to open CoE for precision fermentation bioprocess scale-up in India

In a major boost to Government of India's BioE3 push, German major Glatt and India-based startup PreferCo have announced the launch of \"PreferCo-Glatt Centre of Excellence (CoE) for Bioprocess Scale-Up\" in Hyderabad's Genome Valley.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Women's Health Surge in APAC

The rising burden of diseases such as ovarian cancer, breast cancer, cervical cancer, infertility, etc. is emerging as the key driver of the women's healthcare market across the globe. While North America led the women healthcare market in 2025, Asia Pacific (APAC) is expected to witness the fastest growth this year onwards. As a result, governments across the APAC region, are recognising the importance of women's health and are launching initiatives, particularly under female leaders, to improve access to healthcare services. Moreover, a number of women-led startups are now developing new solutions to address this growing burden of women-associated diseases in the APAC region. Let's take a closer look.

time to read

6 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Hanchor Bio receives US FDA Orphan Drug Designation for HCB101 in gastric cancer

Taiwan-based biotech startup HanchorBio, Inc. has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Daiichi Sankyo names Dr John Tsai as Global Head of R&D

Japan-based Daiichi Sankyo Company has appointed Dr John Tsai to succeed Dr Ken Takeshita, who is stepping down as Global Head of R&D, effective April 1, 2026.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

"The global trend is moving beyond centralised hubs toward distributed networks and domestic capability"

King Faisal Specialist Hospital & Research Centre (KFSHRC) and US-based Germfree Laboratories have announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.

time to read

4 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

SEOUL'S RISKY DRUG PRICING RESET

Drug pricing has once again moved to the centre of policy debate in South Korea, with the government recently stepping back from its proposed generic drug pricing reform.

time to read

2 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Takeda and Iambic sign $1.7 B deal to advance AI driven design of small molecules

Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

S.Biomedics announces partnership with Catalent to develop and manufacture TED-A9

US-based Catalent and South Korea-based S.Biomedics have announced a strategic partnership to support the development and manufacturing of TED-A9, S.Biomedics' allogeneic pluripotent stem-cell-derived ventral midbrain-specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson's disease.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

China revises drug administration regulations to spur innovation

China has revised regulations concerning drug administration in a bid to promote drug innovation, strengthen management of online sales of medicines and reinforce drug safety supervision.

time to read

1 min

BioSpectrum Asia March 2026

Translate

Share

-
+

Change font size